Eczema Studies | Clinical Research Center of Alabama
Eczema Clinical Research Studies
Atopic dermatitis, or eczema, is the most common chronic inflammatory, pruritic skin disease. It causes intense itching and scratching which leads to a severe rash. Recent eczema studies have given researchers more information about this disease, which is leading to a better understanding of the ailment and new treatment options. There are currently a variety of eczema studies available at our center for patients with mild to severe atopic dermatitis. These studies include treatments such as biologics (complicated molecules that are manufactured within a living organism), a topical gel, and an oral medication designed to help decrease extremely itchy skin involved with eczema. These study medications are at the forefront of current medicine and are provided at absolutely no cost, and with no insurance needed. You may also be reimbursed for your time and travel and will receive care from a physician affiliated with the Clinical Research Center of Alabama.
For more information on any of the following eczema clinical research studies, please contact Will O’Donnell by calling 205.209.4179 or emailing [email protected]
Cellgene AD
The purpose of this study is to see if CC-93538 is safe and effective as a possible treatment for your moderate to severe AD. CC-93538 is a biologic agent, called a monoclonal antibody, which is made in a laboratory and designed to stop the body’s own immune (defense) system from reacting to the allergen. CC-93538 does this by blocking a natural substance in the body called interleukin-13 (IL-13). Your body’s immune system makes IL-13. In patients with moderate to severe AD, IL-13 can be found in the skin and is thought to play a role in the allergic response that causes the symptoms of AD, like itching and inflammation of the skin. If CC-93538 can block enough IL-13, then the inflammation in the skin and symptoms, like itch, might be lessened or stopped.
The purpose of this trial is to test if trial treatment with LEO 138559 is safe and better than a placebo (with no active ingredients in it) to potentially treat moderate to severe atopic dermatitis in adults. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and it symptoms, as well as general health status, and quality of life.
Investigational Topical Therapy
The purpose of this study is to assess the safety and efficacy of tapinarof cream, 1% compared to a vehicle cream when applied once daily for 8 weeks for the potential topical treatment of AD. Tapinarof cream, 1%, is an oil-in-water mixture that delivers the active ingredient called tapinarof. The vehicle cream looks like the study treatment but does not contain the active ingredient..
Investigational Topical Study
This study is being done to evaluate the safety and efficacy of ARQ-151 cream in children with mild to moderate eczema (atopic dermatitis) after application once every day for a month. Results will be compared against a vehicle (placebo). The vehicle is a dummy drug made from the same base product used to make ARQ-151 cream, but it does not contain any active study drug. ARQ-151 is a cream that contains the active ingredient roflumilast. Roflumilast is marketed in Canada, the United States, and other countries as a tablet (pill taken by mouth) for flares of a specific chronic lung disease.
MedImmune-AZ AD
The purpose of this study is to assess the effectiveness and safety of the study medication MEDI3506 compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults.
The purpose of this study is to determine if the biologic medication, Dupixent, is effective in treating moderate-to-severe atopic hand and foot dermatitis that has been inadequately responsive to high potency topical steroids.
Become a Participant in our Eczema Studies